進行・再発乳がんに対する化学療法

DOI Web Site

書誌事項

タイトル別名
  • CHEMOTHERAPY FOR ADVANCED AND RECURRENT CARCINOMA IN BREAST
  • シンコウ サイハツ ニュウガン ニ タイスル カガク リョウホウ

この論文をさがす

説明

A study of the therapeutic effect of chemotherapy on recurrent breast carcinoma seen during the period from December 1973 to April 1978 at 14 National Institutes had been done with random selection method.<br>The chemotherapy regimen was as follows;<br>Group A: 5-Fu d. s. 5 mg/kg and Endoxan (tablet) 1 mg/kg<br>Group B: Endoxan (tablet) 2 mg/kg<br>Patients were assessed at the end of a six week period after being given chemotherapy every day, using UICC criteria for therapeutic effect. 73 examples of breast cancer in each group of regimen were treated.<br>Results: Partial remission (P. R.) was found on 7 of 12 metastasized lymph nodes (58.3%) and on 14 of 27 metastasized foci of chest wall and soft tissue (51.4%) in Group A.<br>Comparison of the effective rate for 21/39 (53.8%) in Group A and for 6/36 foci (16.7%) in Group B indicated statistically significant differences (0.05<P<0.10). There were also significant differences 25/73 (34.2%) in Group A from 12/73 (16.4%) in Group B on entire foci involved. Statistic evaluation could not be documented on a few cases with bone, lung and liver metastasis.<br>Chemotherapy regimen was changed to the following drugs from May 1978.<br>Group A: Adriamycin 1 mg/m2 and Endoxan 70 mg/m2 i. v.; 5 to 8 times every one to 2 weeks<br>Group B: 5-Fu 350 mg/m2 and Methotrexate 17 mg/m2 i. v.; 5 to 8 times every one to 2 weeks and Endoxan (tablet) 70 mg/m2; everyday<br>Results: Partial remission was gained on 9/24 cases reported. These foci included 2 of lung and pleural cavity, 2 of bone and 5 of chest wall and soft tissue metastasized.<br>Statistic evaluation could not be reached because of shortage of cases. These results, however, suggest that the effect on further metastasis was noticed rather in this regimen than in previous regimen of only peroral drugs.

収録刊行物

  • 医療

    医療 36 (4), 321-324, 1982

    一般社団法人 国立医療学会

詳細情報 詳細情報について

問題の指摘

ページトップへ